Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02551718 · ClinicalTrials.gov registry record · NA
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT02551718 is a NA study that has completed, run by University of Washington. The registered enrollment target is 34 participants.
The verdict
NCT02551718, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). A high throughput screening assay tests many different drugs individually or in combination that kill leukemia cells in tiny chambers at the same time. High throughput drug sensitivity assay and mutation analysis may help guide the choice most effective for an individual's acute leukemia.
Interventions
- OTHER Cytology Specimen Collection Procedure
- OTHER Chemosensitivity Assay
- GENETIC Gene Expression Analysis
- GENETIC Genetic Variation Analysis
- DRUG In Vitro Sensitivity-Directed Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2015-09-11 |
| Est. Completion | 2021-05-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02551718
The ClinicalTrials.gov registry entry for NCT02551718 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cytology Specimen Collection Procedure is the first listed.
NCT02551718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02551718 about?
NCT02551718 is a clinical study titled "High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia". This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refrac...
What is the current status of trial NCT02551718?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2015-09-11. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT02551718?
The interventions under investigation include: Cytology Specimen Collection Procedure (OTHER), Chemosensitivity Assay (OTHER), Gene Expression Analysis (GENETIC), Genetic Variation Analysis (GENETIC), In Vitro Sensitivity-Directed Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT02551718?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.